The FDA granted orphan designation to a treatment of acute myeloid leukemia being developed by Cero Therapeutics (CERO), according to a post to the agency’s website.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CERO:
- CERo Therapeutics Conducts Reverse Stock Split to Meet Nasdaq Requirements
- CERo Therapeutics Holdings Inc trading halted, news pending
- CERo Therapeutics Announces Reverse Stock Split
- Cero Therapeutics announces 1-for-20 reverse stock split
- Upcoming Stock Splits This Week (June 9 to June 13) – Stay Invested